The former senior director of regulatory affairs at Syner-G Pharm Consulting, Robert Gadimian currently leads Perceptive Regulatory Consulting as president. Robert Gadimian also heads Rophe Pharma and maintains several pipeline programs that develop drugs for maladies such as cystic fibrosis.

An inherited disease, cystic fibrosis results in the buildup of a thick mucus that damages the body’s organs. It is a progressive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene normally regulates salt movement in and out of the cells, but the mutation changes the protein’s function so that it produces a…


Perceptive-Regulatory Consulting, operating out of Burbank, California, is run by Robert Gadimian. Robert Gadimian is also a part of different professional regulatory affairs groups and societies. Perceptive-Regulatory Consulting provides regulatory affairs support to companies and their pre-developed products to get approval from the Food and Drug Administration (FDA).

Getting FDA- approved is the only way to distribute products in the United States legally. However, depending on the product, FDA approval can be fast and easy or long and difficult.

The FDA approval process looks different depending on the product being registered with them. To begin, FDA approval for food is…


Robert Gadimian is the president of Perceptive-Regulatory Consulting in Burbank, California. Robert Gadimian also runs the website Robert-Gadimian.com, which provides services and information related to supplements.

On the matter of supplements vs. food, both can have a wide range of effects on the human body. Supplements can be a good alternative, but it is not always the best option. Compared to food, supplements can lack the capability to provide nutrients the same way food does.

In a study conducted by Dr. Zhang, he sampled 30,899 people to see the difference in intake for adequate vitamin A and magnesium levels from…


Based in Burbank, California, Robert Gadimian leads pharmaceutical regulatory affairs consultancy firm, Perceptive Regulatory Consulting. Robert Gadimian assists drug manufacturers while they go through the Food and Drugs Administration (FDA) approval procedure and still offers his services during the post-approval period.

After a drug has gone through all three phases of clinical trials, the next step is filing, collating, and submitting a new drug application (NDA). It contains the resulting data of the tests and their analysis. The FDA reviews the NDA with three major questions, How safe and effective is it? How appropriate is the intended labeling? How adequate…


Robert Gadimian is a regulatory professional with a quarter of a century’s worth of experience in hands-on drug development. Perceptive Regulatory Consulting, Robert Gadimian’s company, helps drugs and related products get approved by the Federal Drug Administration (FDA) by meeting clinical trials requirements post-Investigational New Drug (IND). His company helps make sure the drugs reach the safety, efficacy, and effectiveness benchmark.

After a drug has gotten an IND status, this means that the FDA has approved it to go into clinical trials. The first thing is to demonstrate the safety observed on animal test subjects and a small number of…


Robert Gadimian is the president of Perceptive Regulatory Consulting, a pharmaceutical development and regulatory affairs company based in Burbank, California. When he is not working, one of Robert Gadimian’s hobbies is playing chess.

One benefit of chess is that it is good for your cognition. It may seem like chess is a simple game that involves moving pieces on a board, but that misconception may change when one sees chess players thinking for minutes about a move before they make it. Playing chess regularly helps people to think effectively on a day-to-day basis.

In fact, chess may improve one’s ability…


Robert Gadimian has had a long career in pharmaceutical regulatory affairs. As the head of Rophe Pharma, Robert Gadimian has a pending patent for a hair growth product.

Statista reports that the number of people that used hair growth/regrowth products in the United States increased from 11.34 million in 2019 to 12.42 million in 2020. It is estimated that the figure will reach 12.94 million in 2024. The materials used in these products are mainly chemicals and minerals already found in the body and hair.

The key ingredient in hair growth is biotin. It supports keratin, the protein substance that…


With a background in pharmaceutical regulatory affairs spanning more than two decades, Robert Gadimian is the president of Rophe Pharma, a startup focused on developing products that are based on innovative uses of already approved drugs. Until now, Robert Gadimian and his C corporation have been working on creating innovative hair growth compounds.

Hair loss has long been a condition for which many people seek effective treatment. Currently, Rophe Pharma is working on experimental data collected from topical use of RPHE-7193 in the treatment of hair loss, which has demonstrated significant results for male pattern blindness. Also known as androgenetic…


A Burbank, California-based regulatory leader in the pharmaceutical industry, Robert Gadimian has acquired almost two decades of global regulatory experience in both Big Pharma and small biotech companies. Robert Gadimian is the founder and president of Rophe Pharma.

A privately owned virtual startup, Rophe Pharma focuses on researching product pipelines that are based on innovative applications of drugs that are already approved. Rophe Pharma approaches its mission with a strong commitment to developing products that can serve the incremental need for differentiated and effective health care solutions. …


An accomplished regulatory consultant with 20 years of experience working at biotechnology and pharmaceutical companies, Robert Gadimian graduated with a master’s degree in pharmacy from Uppsala University Pharmacy School. Robert Gadimian has been actively involved in developing compounds for the treatment of various diseases, including cystic fibrosis.

A genetic condition, cystic fibrosis (CF), is a disease characterized by the production of a faulty protein in cells of tissues and glands that produce mucus and sweat. In a person who does not have CF, mucus is slippery and protects their airway’s linings, digestive tract, and other body organs and tissues. In…

Robert Gadimian

A Burbank, California-based regulatory affairs professional, Robert Gadimian serves as president of Perceptive Regulatory Consulting.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store